Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851002 | 0.95 | CA12 (0.56) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2211024 | 0.86 | CA1 (0.46) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2650277 | 0.85 | CA12 (0.39) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7588248 | 0.85 | ALDH1A1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7708759 | 0.85 | KMT2A (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL109451 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7385067 | 0.83 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1019092 | 0.83 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16617577 | 0.83 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL8570437 | 0.83 | CYP4A11 (0.49) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 607 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093397-B | Compound for treating tumor, synthesis method and application | 自贡市第三人民医院 | 2023-09-05 | — | — | CN | claimed |
| CN-115093397-A | Compound for treating tumor, synthesis method and application | 自贡市第三人民医院 | 2022-09-23 | — | — | CN | claimed |
| CN-113999188-A | Cyperazine hapten and artificial antigen as well as preparation method and application thereof | 中国农业大学 | 2022-02-01 | — | — | CN | claimed |
| CN-109535019-B | 1,1a,6,6 a-tetrahydrocyclopropa [ a ] indene-1-amine derivative and preparation method and application thereof | 华东师范大学 | 2021-08-20 | — | — | CN | claimed |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-12600705-B2 | Heat shock protein modulators and anti-Huntington disease therapeutic agents | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | HOTSPOT THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250275958-A1 | GPCR REGULATOR AND USE THEREOF | Beijing Changping Laboratory (CN) | 2025-09-04 | — | — | US | disclosed |
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| EP-4562015-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4097119-B1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES | UNIV JOHNS HOPKINS (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12291507-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-05-06 | — | — | US | disclosed |
| US-5098996-A | Fluorination of compounds for use in diagnosis of nuclear medicine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-03-24 | — | — | US | disclosed |
| EP-0339549-A2 | Tyr-peptide analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-02 | — | — | EP | disclosed |
| US-4845088-A | ANTIINFLAMMATORY, ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1989-07-04 | — | — | US | disclosed |
| US-4843068-A | INSECTICIDES, MITICIDES, FUNGICIDES | NIHON NOHYAKU CO., LTD. (JP) | 1989-06-27 | — | — | US | disclosed |
| US-4699904-A | ANTIINFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1987-10-13 | — | — | US | disclosed |
| US-4698338-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0234045-A2 | A pyrazole oxime derivative and its production and use | NIHON NOHYAKU CO., LTD. (JP) | 1987-09-02 | — | — | EP | disclosed |
| EP-0207447-A2 | Tetrazolyl derivatives of beta-lactams useful as elastase inhibitors | MERCK & CO. INC. (US) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340552-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | CA1 1979/4885CA2 2447/4885CA12 532/4885 |
| US-12291507-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINH1 | CA1 3092/4885CA2 3231/4885CA12 3334/4885 |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | SERPINA2, SERPINB1, SERPINE1 | CA1 3384/4885CA2 3536/4885CA12 2715/4885 |
| US-12600705-B2 | Heat shock protein modulators and anti-Huntington disease therapeutic agents | HEATR1, HSPH1, HEATR6 | CA1 4173/4885CA2 4052/4885CA12 4705/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | CA1 3203/4885CA2 2255/4885CA12 3818/4885 |
| US-20250275958-A1 | GPCR REGULATOR AND USE THEREOF | ARRB1, GPR3, GPR4 | CA1 4065/4885CA2 1539/4885CA12 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.